Bivalent RSVpreF Vaccine Prevents One Hospitalization Or ED Visit Tied To Infection For Every 250 Vaccinated Older Adults, Analysis Finds

Healio (12/16, Rhoades) reports, “The bivalent respiratory syncytial virus prefusion F, or RSVpreF, vaccine may prevent one hospitalization or ED visit tied to the infection for every 250 vaccinated older adults, an analysis showed.” The new “data are consistent with recent findings on respiratory syncytial virus (RSV) vaccine effectiveness and suggest the opportunity ‘to reduce severe medically attended RSV disease burden,’ the researchers wrote.” The findings were published in JAMA Network Open.